2-Chloro-n-(2,2,2-trifluoroethyl)propanamide, 95+%, 100mg

1-tert-Butyl 3-methyl 3-ethylazetidine-1,3-dicarboxylate, 95.0%, 250mg

Recipiente de cristalización ROTILABO® sin pico, 20 ml, 40 mm, 10 Unidad(es)

10-(tert-Butoxy)-10-oxodecanoic acid, 95.0%, 25g

1,2,4,5-Tetra(1H-imidazol-1-yl)benzene, 98%, 25g

1,1,2,2-Tetrakis(4'-(pyridin-4-yl)-[1,1'-biphenyl]-4-yl)ethene, 97%, 100mg

2-Chloro-4-methoxynicotinaldehyde, 95.0%, 1g

(S)-4,4-DIFLUORO-2-(FLUOROMETHYL)PYRROLIDINE HCL, 95.0%, 100mg

1-Bromo-4-(cyclopentyloxy)benzene, 97%, 5g

2-(Prop-2-en-1-yl)-2H-1,2,3-benzotriazole, 97.0%, 1g

(3-METHYLOXOLAN-3-YL)METHANAMINE, 95.0%, 1g

3-amino-5-bromo-1,3-dihydro-2H-indol-2-one hydrochloride, 95.0%, 5g

(-)-a-Methoxy-a-(trifluoromethyl)phenylacetic acid, 98.0%, 1g